Kazia Therapeutics (KZIA) Stock Forecast & Price Target

Kazia Therapeutics is viewed favorably because paxalisib shows a differentiated, brain-penetrant dual PI3K/mTOR profile with early signals of efficacy across TNBC, HR+/HER2− breast cancer, GBM, and pediatric CNS tumors, while also suggesting biomarker-linked immune and epigenetic activity that may help overcome resistance. The TNBC dataset is particularly compelling, with an 83% ORR and 100% CBR across six evaluable metastatic patients, no paxalisib-related serious adverse events, and translational evidence of reduced exhausted CD8+ T cells and CTC clusters, supporting both mechanism and tolerability. Financially, the program could scale to roughly $580M in peak sales, while GBM adds further optionality given a median OS of 15.54 months versus 11.9 months in GBM-AGILE and nearly $46M in cash to fund development.

Kazia Therapeutics is viewed negatively because its lead asset still faces substantial clinical uncertainty, with the Arm B expansion failing to show adequate response rates or a compelling PFS profile, which materially tempers the case for ~$200M projected TNBC sales and only a 25% probability of success. In pMMR/MSS metastatic colorectal cancer, the company’s rationale for paxalisib is intriguing, but the evidence remains preclinical, so the 52% tumor-burden reduction and added ~50% drop versus anti-PD-1 alone do not yet establish durable human efficacy. The investment case is further weakened by execution and commercialization risks, including dependence on third-party CDMOs, potential trial delays, and meaningful competition in TNBC even if global regulatory approval is eventually achieved.